Zacks Research Analysts Boost Earnings Estimates for Editas Medicine, Inc. (NASDAQ:EDIT)

Editas Medicine, Inc. (NASDAQ:EDIT) – Research analysts at Zacks Research upped their Q3 2025 earnings per share estimates for Editas Medicine in a research note issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the company will earn ($0.74) per share for the quarter, up from their prior estimate of ($0.75). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.61) per share. Zacks Research also issued estimates for Editas Medicine’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.53) EPS.

Several other research analysts also recently commented on the company. Citigroup raised their price objective on Editas Medicine from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. StockNews.com upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Barclays boosted their target price on Editas Medicine from $10.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 29th. Finally, JPMorgan Chase & Co. boosted their price target on Editas Medicine from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Tuesday, February 27th. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Editas Medicine Trading Up 2.3 %

EDIT stock traded up $0.12 during trading on Friday, reaching $5.34. The stock had a trading volume of 173,048 shares, compared to its average volume of 1,802,145. Editas Medicine has a 52 week low of $5.11 and a 52 week high of $11.91. The stock’s 50 day moving average is $7.57 and its two-hundred day moving average is $8.32. The firm has a market cap of $439.16 million, a PE ratio of -2.55 and a beta of 2.01.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.29. Editas Medicine had a negative return on equity of 42.95% and a negative net margin of 196.12%. The firm had revenue of $60.00 million for the quarter, compared to the consensus estimate of $4.84 million. During the same period in the prior year, the company posted ($0.88) earnings per share. The company’s quarterly revenue was up 817.4% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of EDIT. Dimensional Fund Advisors LP grew its stake in Editas Medicine by 40.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,392,396 shares of the company’s stock worth $24,236,000 after purchasing an additional 690,366 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Editas Medicine by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,536,208 shares of the company’s stock worth $66,582,000 after buying an additional 370,734 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in Editas Medicine by 1,183.6% during the 4th quarter. International Assets Investment Management LLC now owns 288,269 shares of the company’s stock worth $28,457,000 after buying an additional 265,812 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Editas Medicine by 32.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 688,964 shares of the company’s stock worth $5,374,000 after buying an additional 170,694 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in Editas Medicine during the 1st quarter worth about $1,097,000. 71.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Editas Medicine

In related news, CEO Gilmore Neil O’neill sold 77,824 shares of Editas Medicine stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $9.42, for a total transaction of $733,102.08. Following the transaction, the chief executive officer now owns 327,470 shares in the company, valued at $3,084,767.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Editas Medicine news, SVP Baisong Mei sold 20,327 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $9.42, for a total transaction of $191,480.34. Following the completion of the sale, the senior vice president now owns 141,543 shares of the company’s stock, valued at $1,333,335.06. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Gilmore Neil O’neill sold 77,824 shares of Editas Medicine stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $9.42, for a total value of $733,102.08. Following the completion of the sale, the chief executive officer now directly owns 327,470 shares of the company’s stock, valued at $3,084,767.40. The disclosure for this sale can be found here. Insiders own 1.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.